首页> 外国专利> Vitamin D derivatives, their manufacturing methods and intermediates, containing cyclised by-product structures, and their use in the manufacture of medicinal products

Vitamin D derivatives, their manufacturing methods and intermediates, containing cyclised by-product structures, and their use in the manufacture of medicinal products

机译:含有环化副产物结构的维生素D衍生物,其制造方法和中间体以及它们在制造医药产品中的用途

摘要

Vitamin D derivatives (I), having a cyclic substituent in the side-chain, are new. Also new are perhydroindane derivative intermediates (A) ands (B). Vitamin D derivatives of formula (I), including all possible epimers, diastereomers and their mixtures, are new. Y1, Y2 = H or -C(O)R5; Y3 (in alpha- or beta-configuration) = H, OH, halo, OC(O)R5 or OR5; R5 = 5-12C aromatic residue; or 1-12C optionally unsaturated alkyl (optionally interrupted by 1 or 2 O, 1 or 2 S and/or 1 or 2 NH; and optionally substituted by 1 or 2 OH, 1 or 2 NH2, 1 or 2 SH, 1 or 2 COOH and/or 1 or 2 COOH); R1, R2 = H or together form exocyclic =CH2; R3, R4 = H, F, Cl, Br or 1-4C alkyl; or CR3R4 = -C(=CH2)- or a 3-7 membered saturated or unsaturated carbocyclic ring; Q = 1-5C n-alkylene; X1, X2 = H, OH, OC(O)R5, F, Cl or Br (but not both OH or both -OC(O)R5); or CX1X2 = C=O; Z' = carbocyclic or heterocyclic (including aromatic or heteroaromatic) ring system comprising a 5- or 6-membered ring optionally fused with a 6-membered ring (optionally substituted by one or more of each of halo, OH, COOR6 or 1-5C alkyl (itself optionally substituted by one or more of halo, 1-6C alkoxy and/or COOR6)); R6 = 1-6C alkyl, benzyl or phenyl. Independent claims are included for: (1) new perhydroindane derivative intermediates of formulae (A) and (B); (2) preparation of perhydroindane derivative intermediates of formula (XIIIa) by: (a) reacting a perhydroindane derivative of formula (A; T replaced by L) with protected, deprotonated propargyl alcohol to give (A; T = -CC-CH2OY5), (b) hydrogenating and deprotecting to give (A; T = -(CH2)3OH), (c) oxidizing to give (A; T = -CH2CH2CHO) and (d) reacting with a nucleophile Nu, cleaving Y4 and oxidizing the free OH group; and (3) preparation of vitamin D compounds of formula (IIa) by: (a) reacting a ketone of formula (XIIIb) with a trimethylsilyl acetoacetate ester in presence of a base or with a Wittig reagent in an aprotic solvent to give (B; U = COOR6), (b) reducing to give (B; U = CH2OH), (c) converting into (B; U replaced by L), (d) converting into the Wittig reagent (B; U = CH2P(O)(G)2) and (e) reacting with a ketone of formula (XXXIII) and optionally deprotecting the product. T = -CC-CH2OY5, -(CH2)3OH or -CH2CH2CHO; Y4 = trialkylsilyl, mixed aryl-alkyl substituted silyl, tetrahydropyranyl or tetrahydrofuranyl protective group; Y5 = tetrahydropyranyl or benzyl; E = side-chain, in which any keto and/or hydroxy groups are protected; U = COOR6, CH2OH or CH2P(O)(G)2; Y6 = 1-6C alkyl, benzyl or phenyl; G = 1-10C alkyl, 1-10C alkoxy, Ph or OPh; L = leaving group; Nu = nucleophile; R7, R8 = H or Me; or together form exocyclic =CH2 or a cyclopropane ring; Y6 = F, (CH2)nOH or (CH2)nOCOR5; n = 0-4; Y'1 = hydroxy-protecting group; Y'3 = H, halo or as Y'1.
机译:在侧链具有环状取代基的维生素D衍生物(I)是新的。全氢茚满衍生物中间体(A)和(B)也是新的。式(I)的维生素D衍生物,包括所有可能的差向异构体,非对映异构体及其混合物,都是新的。 Y1,Y2 = H或-C(O)R5; Y3(α或β构型)= H,OH,卤素,OC(O)R5或OR5; R5 = 5-12C芳族残基;或1-12C任选不饱和烷基(任选被1或2 O,1或2 S和/或1或2 NH中断;并任选被1或2 OH,1或2 NH2、1或2 SH,1或2取代COOH和/或1或2个COOH); R1,R2 = H或一起形成环外= CH2; R3,R4 = H,F,Cl,Br或1-4C烷基;或CR 3 R 4 = -C(= CH 2)-或3-7元饱和或不饱和碳环;或Q = 1-5C正亚烷基; X 1,X 2 = H,OH,OC(O)R 5,F,Cl或Br(但不是OH或两者都是-OC(O)R 5);或CX1X2 = C = O; Z'=碳环或杂环(包括芳族或杂芳族)环系,包含5或6元环,可选地与6元环稠合(可选地被卤素,OH,COOR6或1-5C各自取代一个或多个)烷基(本身任选被卤素,1-6C烷氧基和/或COOR6中的一个或多个取代); R 6 = 1-6C烷基,苄基或苯基。包括以下方面的独立权利要求:(1)式(A)和(B)的新的全氢茚满衍生物中间体; (2)通过以下方法制备式(XIIIa)的全氢茚满衍生物中间体:(a)使式(A; T被L代替)的全氢茚满衍生物与保护的去质子化炔丙醇反应,得到(A; T = -CC-CH 2 OY 5) ,(b)氢化并脱保护得到(A; T =-(CH 2)3 OH),(c)氧化得到(A; T = -CH 2 CH 2 CHO),(d)与亲核试剂Nu反应,裂解Y 4并将其氧化。游离羟基(3)通过以下方法制备式(IIa)的维生素D化合物:(a)使式(XIIIb)的酮与乙酰乙酸三甲基甲硅烷基酯在碱的存在下或与Wittig试剂在非质子溶剂中反应,得到(B ; U = COOR6),(b)还原为(B; U = CH2OH),(c)转化为(B; U被L取代),(d)转化为Wittig试剂(B; U = CH2P(O )(G)2)和(e)与式(XXXIII)的酮反应,并任选使产物脱保护。 T = -CC-CH2OY5,-(CH2)3OH或-CH2CH2CHO; Y4 =三烷基甲硅烷基,混合的芳基-烷基取代的甲硅烷基,四氢吡喃基或四氢呋喃基保护基; Y5 =四氢吡喃基或苄基; E =侧链,其中任何酮和/或羟基被保护; U = COOR6,CH2OH或CH2P(O)(G)2; Y6 = 1-6C烷基,苄基或苯基; G = 1-10C烷基,1-10C烷氧基,Ph或OPh; L =离开组; Nu =亲核试剂; R7,R8 = H或Me;或一起形成环外= CH 2或环丙烷环;或Y6 = F,(CH2)nOH或(CH2)nOCOR5; n = 0-4; Y'1 =羟基保护基; Y'3 = H,卤素或Y'1。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号